Donald L. Hagan LLC Grows Position in Scilex Holding (NASDAQ:SCLX)

Donald L. Hagan LLC boosted its stake in shares of Scilex Holding (NASDAQ:SCLX) by 49.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 52,343 shares of the company’s stock after purchasing an additional 17,245 shares during the period. Donald L. Hagan LLC’s holdings in Scilex were worth $107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. UBS Group AG bought a new stake in shares of Scilex in the fourth quarter worth about $29,000. BlackRock Inc. acquired a new position in Scilex in the first quarter valued at approximately $30,000. Millennium Management LLC purchased a new stake in shares of Scilex in the fourth quarter valued at approximately $45,000. Geode Capital Management LLC purchased a new stake in shares of Scilex in the fourth quarter valued at approximately $47,000. Finally, XTX Topco Ltd purchased a new stake in shares of Scilex in the second quarter valued at approximately $60,000. 69.67% of the stock is currently owned by hedge funds and other institutional investors.

Scilex Stock Performance

Shares of SCLX traded down $0.02 during trading hours on Friday, hitting $1.59. 654,736 shares of the stock were exchanged, compared to its average volume of 1,435,646. The stock’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.61. The company has a market cap of $264.24 million, a price-to-earnings ratio of -1.23 and a beta of 0.76. Scilex Holding has a 12-month low of $0.90 and a 12-month high of $16.90.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Scilex in a research report on Monday, December 4th.

Scilex Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.